Fallopian tube cancer - Pipeline Insight, 2024

Fallopian tube cancer - Pipeline Insight, 2024

DelveInsight’s, “Fallopian tube cancer – Pipeline Insight, 2024,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Fallopian tube cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Fallopian tube cancer Understanding

Fallopian tube cancer: Overview

Fallopian Tube Cancer starts in the fallopian tubes, which connect a woman's ovaries to their uterus. Fallopian Tube Cancer is very rare. Only about 1% of all reproductive cancers in women start in the fallopian tubes. The causes and risk factors for developing primary Fallopian Tube Cancer are not known. In some cases, a woman may have a history of chronic infection and/or inflammation of the fallopian tubes (due to untreated sexually transmitted diseases, for example). It is also believed that not having children and not having used birth control pills can also put a woman at higher risk for developing Fallopian Tube Cancer. The most common symptoms are abnormal vaginal bleeding, vaginal discharge, and/or abdominal pain. It is difficult to see something abnormal growing on the inside of a fallopian tube. This makes Fallopian Tube Cancer difficult to diagnose. One of the most important steps in evaluating any patient with a gynecologic complaint is a proper pelvic examination. The treatment for Fallopian Tube Cancer will take into account the patient's stage of the disease, medical history, current health and personal preference, and other factors. The goal of the treatment of Fallopian Tube Cancer is to get rid of the cancer completely with minimal side effects.

""Fallopian tube cancer - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fallopian tube cancer pipeline landscape is provided which includes the disease overview and Fallopian tube cancer treatment guidelines. The assessment part of the report embraces, in depth Fallopian tube cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fallopian tube cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Fallopian tube cancer R&D. The therapies under development are focused on novel approaches to treat/improve Fallopian tube cancer.

Fallopian tube cancer Emerging Drugs Chapters

This segment of the Fallopian tube cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Fallopian tube cancer Emerging Drugs

• Mirvetuximab Soravtansine: ImmunoGen

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent, to kill the targeted cancer cells. It is currently in phase III stage of development and is being developed by Immunogen.

• Tisotumab vedotin: Genmab/Seagen

Tisotumab vedotin is designed to target tissue factor (TF) using our proprietary antibody–drug conjugate (ADC) technology. TF is highly expressed on many solid tumors, including ovarian, prostate, bladder, esophageal, endometrial, and lung tumors. Tisotumab vedotin is being developed in collaboration with Genmab. It is composed of Genmab’s human monoclonal antibody (mAb) that binds to TF and Seagen’s ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE). It is currently in phase III stage of development.

• Pembrolizumab: Merck & Co.

Keytruda (pembrolizumab) is a drug developed by Merck used in cancer therapy. It is a monoclonal antibody, a protein that binds to specific ligands, which increases the ability of the immune system to help detect and fight tumor cells. Keytruda has already been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancers including melanoma, non-small cell lung cancer, recurrent or metastatic head and neck cancer, classical Hodgkin lymphoma, and urothelial carcinoma. The drug is still under investigation for the treatment of ovarian cancer, Fallopian tube cancer and several other potential disease.

Further product details are provided in the report……..

Fallopian tube cancer: Therapeutic Assessment

This segment of the report provides insights about the different Fallopian tube cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Fallopian tube cancer

There are approx. 70+ key companies which are developing the therapies for Fallopian tube cancer. The companies which have their Fallopian tube cancer drug candidates in the most advanced stage, i.e. Phase III include, ImmunoGen.

• Phases

DelveInsight’s report covers around 70+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Fallopian tube cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Fallopian tube cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fallopian tube cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fallopian tube cancer drugs.

Fallopian tube cancer Report Insights

• Fallopian tube cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Fallopian tube cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Fallopian tube cancer drugs?
• How many Fallopian tube cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fallopian tube cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Fallopian tube cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Fallopian tube cancer and their status?
• What are the key designations that have been granted to the emerging drugs?